Ribon Therapeutics presented molecule inhibitor RBN-2397, the Company’s lead development candidate, at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana.
The firm’s biotechnological advancement is a novel, potent, and selective PARP7 inhibitor that induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors. The presentation featured both pre-clinical and clinical information that supports the further study of RBN-2397.
